Five weeks of insulin-like growth factor-I treatment does not alter glucose kinetics or insulin sensitivity during a hyperglycemic clamp in older women

Metabolism: Clinical and Experimental

Volumn 52, Issue 9, 2003, Pages 1182-1190

  Braun, Barry ^a,b,c   Friedlander, Anne L ^a,b,c   Pollack, Margaret ^a,b,c   Butterfield, Gail E ^a,b,c   Marcus, Robert ^a,b,c   Hoffman, Andrew R ^a,b,c  

^a Geriatric Research   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; ESTROGEN; GESTAGEN; GLUCOSE; INSULIN; PLACEBO; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG USE; ENERGY BALANCE; ENERGY EXPENDITURE; FEMALE; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOSE OXIDATION; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LOW DRUG DOSE; METABOLIC DISORDER; OXIDATION; POSTMENOPAUSE; PRIORITY JOURNAL; STEADY STATE;

EID: 0141459354     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00166-5     Document Type: Article

References (37)

1. Dohm GL, Elton CW, Raju MS, et al.: IGF-I-stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 39:1028-1032, 1990
2. Cusi K, DeFronzo RA: Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type-2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 85:3077-3084, 2000
3. Boulware SD, Tamborlane WV, Matthews LS, et al.: Diverse effects of insulin-like growth factor I on glucose, lipid and amino acid metabolism. Am J Physiol 262:E130-E133, 1992
4. Pratipanawatr T, Pratipanawatr W, Rosen C, et al.: Effect of IGF-I on FFA and glucose metabolism in control and type-2 diabetic subjects. Am J Physiol 282:1360-1368, 2002
5. Hussain MA, Schmitz O, Mengel A, et al.: Insulin-like growth factor I stimulates lipid oxidation, reduced protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 92:2249-2256, 1992
6. Zenobi PD, Graf S, Ursprung H, et al.: Effects of insulin-like growth factor-I on glucose tolerance, insulin levels and insulin secretion. J Clin Invest 89:1908-1913, 1992
7. Sandhu MS, Heald AH, Gibson JM, et al.: Circulating concentrations of insulin-like growth factor I and development of glucose intolerance: A prospective observational study. Lancet 359:1740-1745, 2002
8. Cusi K, DeFronzo RA: Treatment of NIDDM, IDDM and other insulin-resistant states with IGF-I. Diabetes Rev 3:206-236, 1995
9. Schalch DS, Turman NJ, Marcsisin VS, et al.: Short-term effects of human insulin-like growth factor I on metabolic control in patients with type II diabetes mellitus. J Clin Endocrinol Metab 77:1563-1568, 1993
10. Jabri N, Schalch DS, Schwartz SL, et al: Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type-II diabetic patients. Diabetes 43:369-374, 1994
11. Hoffman AR, Pyka G, Liberman SA, et al.: The somatopause, in Muller EE, Cocchi D, Locatelli V (eds): Growth Hormone and Somatomedins During Lifespan. New York, NY, Springer-Verlag, 1993, pp 265-274
12. Donahue LR, Hunter SJ, Sherblom AP, et al.: Age-related changes in serum insulin-like growth factor binding proteins in women. J Clin Endocrinol Metab 71:575-579, 1990
13. Barbieri M, Rizzo MR, Manzella D, et al.: Age-related insulin resistance: Is it an obligatory finding? Lessons from healthy centenarians. Diabetes Metab Res Rev 17:19-26, 2001
14. Walton C, Godsland IF, Proudler AJ, et al.: The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese healthy women. Eur J Clin Invest 23:466-473, 1993
15. Tonino RP: Effect of physical training on the insulin resistance of aging. Am J Physiol 256:E352-E356, 1989
16. Ryan AS: Insulin resistance with aging: Effects of diet and exercise. Sports Med 30:327-346, 2000
17. Butterfield GE, Thompson J, Rennie MJ, et al.: Effect of rhGH and rhIGF-I on protein utilization in elderly women. Am J Physiol E94-E99 1997
18. Thompson JL, Butterfield GE, Marcus R, et al.: The effects of recombinant human insulin-like growth factor I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 80:1845-1852, 1995
19. Toth MJ, Sites CK, Eltabbakh GH, et al. Effect of menopausal status on insulin-stimulated glucose disposal: Comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care 23:801-806, 2000
20. Godsland IF: The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med 240:1-60, 1996 (suppl 738)
21. Crook D, Godsland IF, Hull J, et al.: Hormone replacement therapy with dydrogesterone and 17-β-oestradiol: Effect on serum lipoproteins and glucose tolerance during 24 month follow-up. Br J Obstet Gynaecol 104:298-304, 1997
22. Sites CK, Brochu M, Tchernof A, et al.: Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women. Metabolism 50:835-840, 2001
23. Ryan AS, Nicklas BJ, Berman DM: Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 25:127-133, 2002
24. Brown MD, Korytkowski MT, Zmuda JM, et al.: Insulin sensitivity in postmenopausal women. Diabetes Care 23:1731-1736, 2000
25. Friedlander AL, Butterfield GE, Moynihan S, et al.: One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 86:1496-1503, 2001
26. DeFronzo RA, J Tobin, Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
27. Liu F, Powell DR, Styne DM, et al.: Insulin-like growth factor and insulin-like growth factor binding proteins in the developing rhesus monkey. J Clin Endocrinol Metab 72:905-911, 1991
28. Turkalj I, Keller U, Ninnis R, et al.: Effect of increasing doses of recombinant human insulin-like growth factor I on glucose, lipid and leucine metabolism in man. J Clin Endocrinol Metab 75:1186-1191, 1992
29. Maurus N, Martinez V, Rini A, et al.: Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: Studies on protein, glucose and lipid metabolism. J Clin Endocrinol Metab 85:3036-3042, 2000
30. Lieberman SA, Butterfield GE, Harrison D, et al.: Anabolic effects of recombinant human insulin-like growth factor I in cachectic patents with acquired immunodeficiency syndrome. J Clin Endocrinol Metab 78:404-410, 1994
31. Brussaard HE, Gevers Leuven JA, Frolich M, et al.: Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 40:843-849, 1997
32. Writing Group for the PEPI trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208, 1995
33. Campbell SE, Febbraio MA: Effect of the ovarian hormones on GLUT4 expression and contraction-stimulated glucose uptake. Am J Physiol 282:E1139-E1146, 2002
34. Kelley DE, Mandarino LJ: Fuel selection in human skeletal muscle in insulin resistance: A reexamination. Diabetes 49:677-683, 2000
35. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000
36. Ho JE, Mosca L: Postmenopausal hormone replacement therapy and atherosclerosis. Curr Atheroscler Rep 4:387-395, 2002
37. Bondy CA, Underwood LE, Clemmons DR, et al.: Clinical uses of insulin-like growth factor I. Ann Intern Med 120:593-601, 1994